Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.15)
# 504
Out of 5,124 analysts
503
Total ratings
48.69%
Success rate
14.84%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterates: Neutral | $11 | $11.29 | -2.57% | 17 | Dec 26, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $23 → $26 | $21.70 | +19.82% | 22 | Dec 12, 2025 | |
| RZLT Rezolute | Maintains: Buy | $14 → $5 | $2.36 | +111.86% | 19 | Dec 12, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $34 → $40 | $30.34 | +31.84% | 3 | Dec 9, 2025 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $340 | $294.74 | +15.36% | 30 | Dec 8, 2025 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $1.93 | +521.76% | 18 | Dec 2, 2025 | |
| PCRX Pacira BioSciences | Assumes: Buy | $38 | $25.88 | +46.83% | 3 | Nov 17, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $18.71 | +6.89% | 16 | Nov 11, 2025 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $5 → $4 | $4.02 | -0.50% | 15 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $25.12 | +79.14% | 27 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $774 → $915 | $840.95 | +8.81% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.19 | +630.59% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $87.34 | -8.40% | 35 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1 | $1.58 | -36.71% | 18 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $27.98 | +64.40% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $25.42 | +37.69% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.08 | +127.27% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $6.65 | +200.75% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $79.41 | +48.60% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $46.55 | +74.01% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $44.82 | +18.25% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.43 | +390.54% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $31.12 | +9.25% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $29.04 | -34.57% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.79 | +905.59% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.10 | +32,627.27% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.63 | +513.50% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $182.22 | -0.12% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.71 | +143.19% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $37.36 | -51.82% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $31.21 | -74.37% | 7 | Jun 11, 2019 |
Biohaven
Dec 26, 2025
Reiterates: Neutral
Price Target: $11
Current: $11.29
Upside: -2.57%
Roivant Sciences
Dec 12, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $21.70
Upside: +19.82%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $2.36
Upside: +111.86%
Rapport Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $30.34
Upside: +31.84%
Praxis Precision Medicines
Dec 8, 2025
Reiterates: Buy
Price Target: $340
Current: $294.74
Upside: +15.36%
Daré Bioscience
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.93
Upside: +521.76%
Pacira BioSciences
Nov 17, 2025
Assumes: Buy
Price Target: $38
Current: $25.88
Upside: +46.83%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $18.71
Upside: +6.89%
Minerva Neurosciences
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $4.02
Upside: -0.50%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $25.12
Upside: +79.14%
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $840.95
Upside: +8.81%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.19
Upside: +630.59%
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $87.34
Upside: -8.40%
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.58
Upside: -36.71%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $27.98
Upside: +64.40%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $25.42
Upside: +37.69%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.08
Upside: +127.27%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.65
Upside: +200.75%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $79.41
Upside: +48.60%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $46.55
Upside: +74.01%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $44.82
Upside: +18.25%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.43
Upside: +390.54%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $31.12
Upside: +9.25%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $29.04
Upside: -34.57%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.79
Upside: +905.59%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.10
Upside: +32,627.27%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.63
Upside: +513.50%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $182.22
Upside: -0.12%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.71
Upside: +143.19%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $37.36
Upside: -51.82%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $31.21
Upside: -74.37%